Diffusion Pharmaceutical News Today

/PRNewswire/ -- CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments...

/PRNewswire/ -- EIP Pharma Inc. ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative...

/PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Companys...

EIP Pharma to Present at Canaccord Genuity 43rd Annual Growth Conference BOSTON, MA - August 3, 2023 - EIP Pharma Inc., a clinical stage company focused on developing treatments...

/PRNewswire/ -- EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced that the Companys...

EIP Pharma to Present at JMP Securities Life Sciences Conference BOSTON, MA - May 11, 2023 - EIP Pharma Inc., a clinical stage company focused on developing treatments for... | May 11, 2023

Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) and Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation. Risk & Volatility Cyclerion Therapeutics has a beta of […]

Brokerages expect that Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) will post ($0.04) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Diffusion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.04). Diffusion Pharmaceuticals posted earnings of […]

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) – Zacks Investment Research cut their FY2022 earnings per share estimates for Diffusion Pharmaceuticals in a report issued on Wednesday, March 23rd. Zacks Investment Research analyst D. Bautz now forecasts that the company will post earnings of ($0.17) per share for the year, down from their prior forecast […]

Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference CHARLOTTESVILLE, Va., Jan. 11, 2021 — Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows: Event: Date:  Th...